ArticleEuropean urology open science2026
Oncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Guérin (BCG)-naïve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hyperthermic Intravesical Chemotherapy as a Bladder-Sparing Alternative to BCG in the Management of Non-Muscle-Invasive Bladder Cancer: A Systematic Review of Oncological Outcomes in the Era of BCG Shortage.Journal of clinical medicine · 2026Review
- Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Intravesical instillation of bacillus Calmette-Guérin (BCG) is the standard therapy for patients with intermediate-risk or high-risk non-muscle-invasive bladder cancer. In cases of BCG failure, device-assisted hyperthermic intravesical chemotherapy (HIVEC) using epirubicin can be offered to patients who are unfit for or decline radical cystectomy. The aim of this study was to investigate long-term oncological outcomes for patients treated with HIVEC in a first-line or second-line setting. Methods: We retrospectively analyzed our prospective database of patients who underwent HIVEC with epirubicin between November 2016 and December 2024 at two Swiss university centers. Survival was assessed using Kaplan-Meier curves and log-rank tests. Cox regression models were used to explore associations between clinicopathological variables and time-to-event outcomes. Key findings and limitations: Of the 88 patients included, 23 (26.1%) received HIVEC as first-line treatment and 65 (73.9%) after BCG failure. Median follow-up was 38 mo (interquartile range 22-54). Intravesical recurrence was observed in 26 patients (29.6%), with 1-yr and 2-yr intravesical recurrence-free survival rates of 84.1% and 77.3%, respectively. Extravesical recurrence in the upper urinary tract or prostatic urethra occurred in 21 patients (23.9%). Progression to muscle-invasive or metastatic disease due to intravesical recurrence was observed in eight patients (9.1%), with 1-yr and 2-yr progression-free survival rates of 96.6% and 93.2%, respectively. Conclusions and clinical implications: Device-assisted epirubicin-based HIVEC yielded encouraging long-term oncological outcomes both for first-line therapy and after BCG failure. Extravesical recurrences were observed at a relatively high rate in the group with BCG failure, which highlights the importance of monitoring for extravesical disease in future studies and follow-up planning. Prospective studies are needed to confirm the efficacy of epirubicin-based HIVEC, particularly in first-line settings. Patient summary: We tested in-bladder treatment with a heated solution of a chemotherapy drug for patients with recurrence of non-muscle-invasive bladder cancer after failure of BCG (bacillus Calmette-Guérin) therapy. Our results show promising cancer control rates after BCG failure, and suggest that this treatment may also be a valuable option when BCG is unavailable and in patients for whom BCG is not suitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.